231 related articles for article (PubMed ID: 32856614)
1. Lung Cancer and Immunity Markers.
Lim RJ; Liu B; Krysan K; Dubinett SM
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2423-2430. PubMed ID: 32856614
[TBL] [Abstract][Full Text] [Related]
2. Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment.
Saab S; Zalzale H; Rahal Z; Khalifeh Y; Sinjab A; Kadara H
Front Immunol; 2020; 11():159. PubMed ID: 32117295
[TBL] [Abstract][Full Text] [Related]
3. Early Diagnosis and Screening for Lung Cancer.
Kadara H; Tran LM; Liu B; Vachani A; Li S; Sinjab A; Zhou XJ; Dubinett SM; Krysan K
Cold Spring Harb Perspect Med; 2021 Sep; 11(9):. PubMed ID: 34001525
[TBL] [Abstract][Full Text] [Related]
4. Genomic approaches to accelerate cancer interception.
Beane J; Campbell JD; Lel J; Vick J; Spira A
Lancet Oncol; 2017 Aug; 18(8):e494-e502. PubMed ID: 28759388
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive Diagnostics for Early Detection of Lung Cancer: Challenges and Potential with a Focus on Changes in DNA Methylation.
Farooq M; Herman JG
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2416-2422. PubMed ID: 33148791
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers for Lung Cancer Screening and Detection.
Ostrin EJ; Sidransky D; Spira A; Hanash SM
Cancer Epidemiol Biomarkers Prev; 2020 Dec; 29(12):2411-2415. PubMed ID: 33093160
[TBL] [Abstract][Full Text] [Related]
7. The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy.
Krysan K; Tran LM; Grimes BS; Fishbein GA; Seki A; Gardner BK; Walser TC; Salehi-Rad R; Yanagawa J; Lee JM; Sharma S; Aberle DR; Spira AE; Elashoff DA; Wallace WD; Fishbein MC; Dubinett SM
Cancer Res; 2019 Oct; 79(19):5022-5033. PubMed ID: 31142513
[TBL] [Abstract][Full Text] [Related]
8. Proteomic approaches in lung cancer biomarker development.
Cho JY; Sung HJ
Expert Rev Proteomics; 2009 Feb; 6(1):27-42. PubMed ID: 19210125
[TBL] [Abstract][Full Text] [Related]
9. Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade.
Biton J; Ouakrim H; Dechartres A; Alifano M; Mansuet-Lupo A; Si H; Halpin R; Creasy T; Bantsimba-Malanda C; Arrondeau J; Goldwasser F; Boudou-Rouquette P; Fournel L; Roche N; Burgel PR; Goc J; Devi-Marulkar P; Germain C; Dieu-Nosjean MC; Cremer I; Herbst R; Damotte D
Am J Respir Crit Care Med; 2018 Oct; 198(7):928-940. PubMed ID: 29518341
[TBL] [Abstract][Full Text] [Related]
10. Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges.
Kunimasa K; Goto T
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31963413
[TBL] [Abstract][Full Text] [Related]
11. Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma.
Zhang C; Zhang J; Xu FP; Wang YG; Xie Z; Su J; Dong S; Nie Q; Shao Y; Zhou Q; Yang JJ; Yang XN; Zhang XC; Li Z; Wu YL; Zhong WZ
J Thorac Oncol; 2019 Nov; 14(11):1912-1923. PubMed ID: 31446140
[TBL] [Abstract][Full Text] [Related]
12. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology.
Hirsch FR; Franklin WA; Gazdar AF; Bunn PA
Clin Cancer Res; 2001 Jan; 7(1):5-22. PubMed ID: 11205917
[TBL] [Abstract][Full Text] [Related]
13. Advances and challenges in cancer immunoprevention and immune interception.
Stanton SE; Castle PE; Finn OJ; Sei S; Emens LA
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38519057
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer.
Leonetti A; Wever B; Mazzaschi G; Assaraf YG; Rolfo C; Quaini F; Tiseo M; Giovannetti E
Drug Resist Updat; 2019 Sep; 46():100644. PubMed ID: 31585395
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.
Yang J; Chen J; Wei J; Liu X; Cho WC
Expert Opin Biol Ther; 2016 Oct; 16(10):1209-23. PubMed ID: 27426430
[TBL] [Abstract][Full Text] [Related]
16. Systematic review of radiomic biomarkers for predicting immune checkpoint inhibitor treatment outcomes.
Zhang C; de A F Fonseca L; Shi Z; Zhu C; Dekker A; Bermejo I; Wee L
Methods; 2021 Apr; 188():61-72. PubMed ID: 33271285
[TBL] [Abstract][Full Text] [Related]
17. TIME for Bugs: The Immune Microenvironment and Microbes in Precancer.
Borthwick Bowen M; Helmink BA; Wargo JA; Yates MS
Cancer Prev Res (Phila); 2023 Sep; 16(9):497-505. PubMed ID: 37428011
[TBL] [Abstract][Full Text] [Related]
18. Early Events in the Molecular Pathogenesis of Lung Cancer.
Kadara H; Scheet P; Wistuba II; Spira AE
Cancer Prev Res (Phila); 2016 Jul; 9(7):518-27. PubMed ID: 27006378
[TBL] [Abstract][Full Text] [Related]
19. Biological markers in lung cancer: A clinician's perspective.
Tufman A; Huber RM
Cancer Biomark; 2010; 6(3-4):123-35. PubMed ID: 20660959
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors in advanced non-small cell lung cancer.
Assi HI; Kamphorst AO; Moukalled NM; Ramalingam SS
Cancer; 2018 Jan; 124(2):248-261. PubMed ID: 29211297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
